Constitutive nitric oxide synthases in the heart from hypertrophy to failure
- PMID: 18307746
- DOI: 10.1111/j.1440-1681.2008.04901.x
Constitutive nitric oxide synthases in the heart from hypertrophy to failure
Abstract
1. Endogenous myocardial nitric oxide (NO) may modulate the transition from adaptive to maladaptive hypertrophy leading to heart failure. This review summarizes the information on the interrelations between the precise localization of NO synthases (NOS) and their regulatory functions within different compartments of the heart. 2. In rodent models of pressure overload or myocardial infarction, the three NOS isoforms (NOS1, NOS2, NOS3) were shown to play a neutral, protective, or even adverse role in myocardial remodelling, depending on the NOS activity, the location of each NOS and their regulators. 3. The analysis of conditions that modulate the expression of NOS1 and NOS3 in the heart according to physiopathological situations, indicated that, beside the level of total NOS activity, unique changes in NO compartmentation secondary to NOS1 or NOS3 subcellular location might be involved in the development of cardiac hypertrophy and failure. 4. Thus, different circuits in NO-signalling pathways in myocardium might be activated and this principle is a key to understand contradictions existing in NO biology in the heart. Unravelling the mechanisms behind the NO, NOS and cardiac function is still an ongoing challenge.
Similar articles
-
[Significance of neuronal, endothelial and inducible NO-synthase isoforms in the cardiac muscle histophysiology].Morfologiia. 2006;129(1):7-17. Morfologiia. 2006. PMID: 17201313 Review. Russian.
-
Cardiac myocyte neuronal nitric oxide synthase. New therapeutic target in heart failure?Arch Mal Coeur Vaiss. 2005 Dec;98(12):1244-8. Arch Mal Coeur Vaiss. 2005. PMID: 16435605 Review.
-
Deficiency of different nitric oxide synthase isoforms activates divergent transcriptional programs in cardiac hypertrophy.Physiol Genomics. 2003 Jun 24;14(1):25-34. doi: 10.1152/physiolgenomics.00156.2002. Physiol Genomics. 2003. PMID: 12709511
-
Cardiomyocyte-specific overexpression of nitric oxide synthase 3: impact on left ventricular function and myocardial infarction.Trends Cardiovasc Med. 2005 Oct;15(7):249-53. doi: 10.1016/j.tcm.2005.07.005. Trends Cardiovasc Med. 2005. PMID: 16226679 Review.
-
Up-regulation of cardiac nitric oxide synthase 1-derived nitric oxide after myocardial infarction in senescent rats.FASEB J. 2003 Oct;17(13):1934-6. doi: 10.1096/fj.02-1208fje. Epub 2003 Aug 1. FASEB J. 2003. PMID: 12897062
Cited by
-
Autophagy in ischemic heart disease.Circ Res. 2009 Jan 30;104(2):150-8. doi: 10.1161/CIRCRESAHA.108.187427. Circ Res. 2009. PMID: 19179668 Free PMC article. Review.
-
Ouabain increases iNOS-dependent nitric oxide generation which contributes to the hypertrophic effect of the glycoside: possible role of peroxynitrite formation.Mol Cell Biochem. 2012 Apr;363(1-2):323-33. doi: 10.1007/s11010-011-1185-7. Epub 2011 Dec 10. Mol Cell Biochem. 2012. PMID: 22160804
-
Oxidative Stress in Cardiovascular Diseases.Antioxidants (Basel). 2020 Sep 14;9(9):864. doi: 10.3390/antiox9090864. Antioxidants (Basel). 2020. PMID: 32937950 Free PMC article. Review.
-
Neuronal NO synthase mediates plenylephrine induced cardiomyocyte hypertrophy through facilitation of NFAT-dependent transcriptional activity.Biochem Biophys Rep. 2019 Mar 11;18:100620. doi: 10.1016/j.bbrep.2019.100620. eCollection 2019 Jul. Biochem Biophys Rep. 2019. PMID: 30899802 Free PMC article.
-
Cyclic GMP signaling in cardiovascular pathophysiology and therapeutics.Pharmacol Ther. 2009 Jun;122(3):216-38. doi: 10.1016/j.pharmthera.2009.02.009. Epub 2009 Mar 21. Pharmacol Ther. 2009. PMID: 19306895 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical